Video Latest - ecancer

PDL1 and other biomarkers for selecting patients for immune checkpoint therapies

Dr Mary O'Brien - The Royal Marsden NHS Foundation Trust, London, UK

14 Sep 2016

Maintenance in NSCLC

Dr Benjamin Besse - Institut Gustave Roussy, Paris, France

14 Sep 2016

Editor's Choice for August 2016

Prof Gordon McVie - Editor in Chief, ecancer

22 Aug 2016

Breast cancer in the 21st century

Prof Debu Tripathy - MD Anderson Cancer Center, Texas, USA

25 Jul 2016

Developments in gastrointestinal tumour treatment

Dr Ihor Pidhorecky - Memorial Cancer Institute, Hollywood, Florida, USA

25 Jul 2016

Editor's Choice for July 2016

Prof Gordon McVie - Editor in Chief, ecancer

25 Jul 2016

The steady progress of targeted therapies

Dr Anton Berns - Netherlands Cancer Institute, Amsterdam, Netherlands

20 Jul 2016

Prof Michael Seckl: Why attend Future Horizons in Lung Cancer?

Prof Michael Seckl - Imperial College London, London

17 Jul 2016

Polygenic risk and the targeted prevention of cancer

Prof Paul Pharoah - University of Cambridge, Cambridge, UK

13 Jul 2016

Combination trial designs: efficient, effective and tolerable regimens

Dr Susan Galbraith – AstraZeneca, Macclesfield, UK

4 Jul 2016

WIN 2016 highlights: Changing the understanding of cancer

Prof Richard Schilsky - Chief Medical Officer of the American Society of Oncology (ASCO)

1 Jul 2016

Results of the MINDACT clinical trial

Dr Suzette Delaloge - Institut Gustave Roussy, Paris, France

1 Jul 2016

Video